JP5544660B2 - ヒトアドレナリンβ３受容体リガンド、これを含む食品及び医薬品 - Google Patents

ヒトアドレナリンβ３受容体リガンド、これを含む食品及び医薬品 Download PDF

Info

Publication number
JP5544660B2
JP5544660B2 JP2010516877A JP2010516877A JP5544660B2 JP 5544660 B2 JP5544660 B2 JP 5544660B2 JP 2010516877 A JP2010516877 A JP 2010516877A JP 2010516877 A JP2010516877 A JP 2010516877A JP 5544660 B2 JP5544660 B2 JP 5544660B2
Authority
JP
Japan
Prior art keywords
acid
day
component
receptor
adrenergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010516877A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2009151094A1 (ja
Inventor
康雄 藤本
昭一 栗原
忠生 浜屋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ricom Corp
Original Assignee
Ricom Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ricom Corp filed Critical Ricom Corp
Priority to JP2010516877A priority Critical patent/JP5544660B2/ja
Publication of JPWO2009151094A1 publication Critical patent/JPWO2009151094A1/ja
Application granted granted Critical
Publication of JP5544660B2 publication Critical patent/JP5544660B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2010516877A 2008-06-11 2009-06-11 ヒトアドレナリンβ３受容体リガンド、これを含む食品及び医薬品 Active JP5544660B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010516877A JP5544660B2 (ja) 2008-06-11 2009-06-11 ヒトアドレナリンβ３受容体リガンド、これを含む食品及び医薬品

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2008153390 2008-06-11
JP2008153390 2008-06-11
PCT/JP2009/060682 WO2009151094A1 (ja) 2008-06-11 2009-06-11 ヒトアドレナリンβ3受容体リガンド、これを含む食品及び医薬品
JP2010516877A JP5544660B2 (ja) 2008-06-11 2009-06-11 ヒトアドレナリンβ３受容体リガンド、これを含む食品及び医薬品

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014013224A Division JP2014080432A (ja) 2008-06-11 2014-01-28 ヒトアドレナリンβ３受容体リガンド、これを含む食品及び医薬品

Publications (2)

Publication Number Publication Date
JPWO2009151094A1 JPWO2009151094A1 (ja) 2011-11-17
JP5544660B2 true JP5544660B2 (ja) 2014-07-09

Family

ID=41416798

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010516877A Active JP5544660B2 (ja) 2008-06-11 2009-06-11 ヒトアドレナリンβ３受容体リガンド、これを含む食品及び医薬品
JP2014013224A Pending JP2014080432A (ja) 2008-06-11 2014-01-28 ヒトアドレナリンβ３受容体リガンド、これを含む食品及び医薬品

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014013224A Pending JP2014080432A (ja) 2008-06-11 2014-01-28 ヒトアドレナリンβ３受容体リガンド、これを含む食品及び医薬品

Country Status (7)

Country Link
US (1) US20110098358A1 (enExample)
EP (1) EP2316445A4 (enExample)
JP (2) JP5544660B2 (enExample)
KR (1) KR101274543B1 (enExample)
CN (1) CN102149375B (enExample)
CA (1) CA2727223C (enExample)
WO (1) WO2009151094A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016071180A1 (en) * 2014-11-03 2016-05-12 Nestec S.A. Methods using facial temperature to evaluate post-ingestive impact of food ingredients on fat oxidation
US9561206B2 (en) * 2015-01-07 2017-02-07 The United States Of America, As Represented By The Secretary Of The Navy Use of heptadecanoic acid (C17:0) to detect risk of and treat hyperferritinemia and metabolic syndrome
AU2018354090B2 (en) 2017-10-23 2024-10-24 Epitracker, Inc. Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome
AU2019274431B2 (en) 2018-05-23 2025-03-13 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
WO2020146263A1 (en) 2019-01-09 2020-07-16 Epitracker, Inc. Compositions and methods for diagnosis and treatment of neurodegenerative diseases
JP7404382B2 (ja) 2019-03-04 2023-12-25 エピトラッカー インコーポレイテッド 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用
JP7500037B2 (ja) * 2019-07-24 2024-06-17 国立大学法人 東京大学 血中尿酸値低下剤及び血中尿酸値低下用食品組成物
US12370166B2 (en) 2021-11-03 2025-07-29 Epitracker, Inc. Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031240A1 (en) * 1995-04-07 1996-10-10 Brandeis University Increasing the hdl level and the hdl/ldl ratio in human serum by balancing saturated and polyunsaturated dietary fatty acids
JP2005179264A (ja) * 2003-12-19 2005-07-07 Shokubutsu Kogaku Kenkyusho:Kk 体重増加抑制剤
WO2008000440A1 (en) * 2006-06-27 2008-01-03 Lipid Nutrition B.V. Use of a polyunsaturated fatty acid compound

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2173545C (en) * 1995-04-07 2004-06-29 Kalyana Sundram Increasing the hdl level and the hdl/ldl ratio in human serum by balancing saturated and polyunsaturated dietary fatty acids
EP1285590A1 (en) * 2001-08-08 2003-02-26 Société des Produits Nestlé S.A. Lipid blends
US7687074B2 (en) * 2001-08-23 2010-03-30 Westgate Biological Ltd. Use of milk serum apoproteins in the treatment of microbial or viral infection
WO2003099304A1 (en) * 2002-05-27 2003-12-04 Morinaga & Co., Ltd. Composition against periodontal bacteria and foods, drinks and mouth washers against periodontal bacteria containing the composition
JP2004075653A (ja) * 2002-06-19 2004-03-11 Nisshin Oillio Ltd 体脂肪分解促進剤および飲食物
AU2003261926A1 (en) * 2002-09-05 2004-03-29 The Nisshin Oillio Group, Ltd. Slimming agents and foods and drinks comprising the same
JPWO2004022050A1 (ja) * 2002-09-05 2005-12-22 日清オイリオグループ株式会社 脂質代謝調整剤および飲食物
CN1330671C (zh) 2002-10-08 2007-08-08 株式会社利根 含脱乙酰壳多糖的多糖、其制备方法和用途
JP2006096666A (ja) 2002-10-31 2006-04-13 Kaneka Corp 選択的ヒトβ３アドレナリン受容体アゴニスト剤
JP2005015358A (ja) * 2003-06-25 2005-01-20 Pharma Design Inc 摂食障害の治療に供される医薬組成物
AU2004285803A1 (en) * 2003-11-04 2005-05-12 Meiji Dairies Corporation Plant-origin beta3-adrenoceptor agonist and use of the same
US20060084637A1 (en) * 2004-10-18 2006-04-20 Maria Alemany Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same
EP1834639B8 (en) * 2005-01-04 2016-12-07 Mochida Pharmaceutical Co., Ltd. Remedial agent for fat toxicity
US20080200707A1 (en) * 2005-01-04 2008-08-21 Mochida-Pharmaceuticals Pharmaceutical Co., Ltd. Lipotoxicity Relieving Agent
GB0514463D0 (en) * 2005-01-31 2005-08-17 Loders Croklaan Bv Use of pinolenic acid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031240A1 (en) * 1995-04-07 1996-10-10 Brandeis University Increasing the hdl level and the hdl/ldl ratio in human serum by balancing saturated and polyunsaturated dietary fatty acids
JP2005179264A (ja) * 2003-12-19 2005-07-07 Shokubutsu Kogaku Kenkyusho:Kk 体重増加抑制剤
WO2008000440A1 (en) * 2006-06-27 2008-01-03 Lipid Nutrition B.V. Use of a polyunsaturated fatty acid compound

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6009041483; Ｂａｒｒｅ　Ｄ．　Ｅ．: 'Ｐｏｔｅｎｔｉａｌ　ｏｆ　Ｅｖｅｎｉｎｇ　Ｐｒｉｍｒｏｓｅ，　Ｂｏｒａｇｅ，　Ｂｌａｃｋ　Ｃｕｒｒａｎｔ，　ａｎｄ　Ｆｕｎｇａｌ　Ｏｉｌｓ　ｉｎ　Ｈｕｍａｎ　Ｈｅａｌｔｈ' Ｎｕｔｒｉｔｉｏｎ　＆　Ｍｅｔａｂｏｌｉｓｍ Ｖｏｌ．４５, 2001, ｐ．４７-５７ *
JPN6013036925; Ｅｍｉｌｉｏ　Ｈｅｒｒｅｒａ，　Ｅｎｃａｒｎａｃｉｏｎ　Ａｍｕｓｑｕｉｖａｒ，　ａｎｄ　Ｊｕｄｉｔｈ　Ｃａｃｈｏ: 'Ｃｈａｎｇｅｓ　ｉｎ　ｄｉｅｔａｒｙ　ｆａｔｔｙ　ａｃｉｄｓ　ｍｏｄｉｆｙ　ｔｈｅ　ｄｅｃｒｅａｓｅｄ　ｌｉｐｏｌｙｔｉｃ　beta３-ａｄｒｅｎｅｒｇｉｃ　ｒｅｓｐｏｎｓｅ　ｔｏ　ｈｙｐｅｒｉｎｓｕｌｉ' Ｍｅｔａｂｏｌｉｓｍ Ｖｏｌｕｍｅ４９，　Ｉｓｓｕｅ９, 200009, １１８０-１１８７, Ｅｌｓｅｖｉｅｒ *

Also Published As

Publication number Publication date
CN102149375B (zh) 2015-09-30
EP2316445A4 (en) 2011-12-21
JPWO2009151094A1 (ja) 2011-11-17
KR20110017437A (ko) 2011-02-21
US20110098358A1 (en) 2011-04-28
JP2014080432A (ja) 2014-05-08
EP2316445A1 (en) 2011-05-04
CA2727223C (en) 2014-10-07
WO2009151094A1 (ja) 2009-12-17
CN102149375A (zh) 2011-08-10
KR101274543B1 (ko) 2013-06-17
CA2727223A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
JP5544660B2 (ja) ヒトアドレナリンβ３受容体リガンド、これを含む食品及び医薬品
CN107428652B (zh) 用于治疗炎性疾病、退行性疾病和神经退行性疾病的化合物、组合物和方法
EP3157936B1 (en) Mineral amino-acid complexes of active agents
JP2011063557A (ja) Ｐｐａｒ活性化剤
JP5770449B2 (ja) ＰＰＡＲα活性化剤
CA2966574C (en) Agents for maintaining undifferentiated state and promoting proliferation of stem cells
HK1157216A (en) Human b3 adrenergic receptor ligand, and food or pharmaceutical product containing the same
WO2007040006A1 (ja) ペルオキシソーム増殖剤応答性受容体ＰＰＡＲγ活性化剤、および該活性化剤を含有する特定症状の予防または改善用組成物
US10925849B2 (en) Method of treatment of obesity
JP2019172614A (ja) 遺伝子発現制御剤及び筋委縮の抑制剤、予防剤又は改善剤
US20100028465A1 (en) Composition for ameliorating cerebral function
JP2015193547A (ja) 運動様作用を有するレスベラトロール加熱処理組成物
JPWO2006068075A1 (ja) ペルオキシソーム増殖剤応答性受容体γリガンド剤
KR20210016163A (ko) 커큐민 및 다가 불포화 지방산을 유효성분으로 함유하는 관절염의 예방 및 치료용 조성물
JP2010090097A (ja) 抗骨粗鬆症組成物
EP1915142A1 (en) Composition comprising oleic acid and the use thereof
EP2805717A1 (en) Appetite suppressant
JP2010095456A (ja) 脂質代謝改善剤
JP2007230912A (ja) 神経再生促進剤、および該促進剤を含む機能性食品
JP2015124151A (ja) レスベラトロール加熱処理組成物
JP2010059106A (ja) 糖尿病進行抑制作用を有する組成物
JP2019210239A (ja) ８−ヒドロキシエイコサペンタエン酸の薬理用途
JP2012131761A (ja) 抗炎症剤
JP2018008893A (ja) 高血糖抑制剤
JP2016124850A (ja) 抗肥満剤

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130926

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140128

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140325

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140421

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140425

R150 Certificate of patent or registration of utility model

Ref document number: 5544660

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250